366 related articles for article (PubMed ID: 6142304)
1. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.
Starzl TE; Nalesnik MA; Porter KA; Ho M; Iwatsuki S; Griffith BP; Rosenthal JT; Hakala TR; Shaw BW; Hardesty RL
Lancet; 1984 Mar; 1(8377):583-7. PubMed ID: 6142304
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection.
Ho M; Miller G; Atchison RW; Breinig MK; Dummer JS; Andiman W; Starzl TE; Eastman R; Griffith BP; Hardesty RL
J Infect Dis; 1985 Nov; 152(5):876-86. PubMed ID: 2995512
[TBL] [Abstract][Full Text] [Related]
3. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
Walker RC; Paya CV; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; Daly RC; McGregor CG
J Heart Lung Transplant; 1995; 14(2):214-21. PubMed ID: 7779838
[TBL] [Abstract][Full Text] [Related]
4. Posttransplantation cyclosporine-induced lymphoproliferative disorders: clinical and radiologic manifestations.
Harris KM; Schwartz ML; Slasky BS; Nalesnik M; Makowka L
Radiology; 1987 Mar; 162(3):697-700. PubMed ID: 3544033
[TBL] [Abstract][Full Text] [Related]
5. Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: a growing concern.
Malatack JF; Gartner JC; Urbach AH; Zitelli BJ
J Pediatr; 1991 May; 118(5):667-75. PubMed ID: 1850458
[TBL] [Abstract][Full Text] [Related]
6. Lymphoma in organ transplant recipients.
Lancet; 1984 Mar; 1(8377):601-3. PubMed ID: 6142310
[No Abstract] [Full Text] [Related]
7. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone.
Wilkinson AH; Smith JL; Hunsicker LG; Tobacman J; Kapelanski DP; Johnson M; Wright FH; Behrendt DM; Corry RJ
Transplantation; 1989 Feb; 47(2):293-6. PubMed ID: 2645716
[TBL] [Abstract][Full Text] [Related]
8. Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression.
Melosky B; Karim M; Chui A; McBride M; Cameron EC; Yeung CK; Landsberg D; Shackleton C; Keown PA
J Am Soc Nephrol; 1992 Jun; 2(12 Suppl):S290-4. PubMed ID: 1323341
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients.
Starzl TE; Klintmalm GB; Weil R; Porter KA; Iwatsuki S; Schroter GP; Fernandez-Bueno C; MacHugh N
Surg Gynecol Obstet; 1981 Oct; 153(4):486-94. PubMed ID: 6269238
[TBL] [Abstract][Full Text] [Related]
10. Studies on long-term T-cell-mediated immunity to Epstein-BArr virus in immunosuppressed renal allograft recipients.
Crawford DH; Edwards JM; Sweny P; Hoffbrand AV; Janossy G
Int J Cancer; 1981 Dec; 28(6):705-9. PubMed ID: 6277797
[TBL] [Abstract][Full Text] [Related]
11. Unusual lymphoproliferative oropharyngeal lesions in heart and heart-lung transplant recipients.
Fairley JW; Hunt BJ; Glover GW; Radley-Smith RC; Yacoub MH
J Laryngol Otol; 1990 Sep; 104(9):720-4. PubMed ID: 2230584
[TBL] [Abstract][Full Text] [Related]
12. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?
Burra P; Buda A; Livi U; Rigotti P; Zanus G; Calabrese F; Caforio A; Menin C; Canova D; Farinati F; Luciana Aversa SM
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1065-70. PubMed ID: 16957512
[TBL] [Abstract][Full Text] [Related]
13. Lymphomas and lymphoproliferative lesions developing under cyclosporin therapy.
Beveridge T; Krupp P; McKibbin C
Lancet; 1984 Apr; 1(8380):788. PubMed ID: 6143097
[No Abstract] [Full Text] [Related]
14. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome.
Ben-Ari Z; Amlot P; Lachmanan SR; Tur-Kaspa R; Rolles K; Burroughs AK
Liver Transpl Surg; 1999 May; 5(3):184-91. PubMed ID: 10226108
[TBL] [Abstract][Full Text] [Related]
15. Lymphoproliferative disorders and hematologic malignancies following organ transplantation.
Ferry JA; Jacobson JO; Conti D; Delmonico F; Harris NL
Mod Pathol; 1989 Nov; 2(6):583-92. PubMed ID: 2587566
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
[TBL] [Abstract][Full Text] [Related]
17. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder.
Purighalla R; Shapiro R; Jordan ML; Scantlebury VP; Gritsch HA; Vivas C; Randhawa PS
Clin Transplant; 1997 Dec; 11(6):574-6. PubMed ID: 9408687
[TBL] [Abstract][Full Text] [Related]
18. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
19. Posttransplant lymphoproliferative disorders in heart-lung transplant recipients: primary presentation in the allograft.
Yousem SA; Randhawa P; Locker J; Paradis IL; Dauber JA; Griffith BP; Nalesnik MA
Hum Pathol; 1989 Apr; 20(4):361-9. PubMed ID: 2539321
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus serology and Epstein-Barr virus-associated lymphoproliferative disorders in pediatric liver transplant recipients.
Sokal EM; Caragiozoglou T; Lamy M; Reding R; Otte JB
Transplantation; 1993 Dec; 56(6):1394-8. PubMed ID: 8279009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
